Ola Myklebost group

 

Activities

The Mesenchymal Biology and Oncogenesis Group studies how mesenchymal cells differentiate and how these processes may be deranged in cancer. Studies are partly carried out in immortalised normal mesenchymal stem-like cells derived from bone marrow (MSC), and partly in cell lines derived from tow types of mesenchymal cancer, osteo- and liposarcomas. We have made our own immortalised MSC line, iMSC#3, which can differentiate in vitro towards adipocytes and osteocytes, the cell type the lipo- and osteosarcoma resemble. Our projects that relate to the Stem Cell Centre concern three issues:

1. How stem cell fates and MSC functions are regulated by the balance of Let-7 microRNAs and the architectural transcription factor HMGA2 (Marianne Stabell, Åshild Breivik, Russell Castro)

2. How microRNAs regulate mesenchymal differentiation (Magne Skårn, Heidi Namløs, Leonardo Meza-Zepeda)

3. Epigenetic regulation of osteogenic differentiation of MSCs (Anne-Mari Håkelien, Susanne Lorentz, Eivind Valen Egeland, Leonardo Meza-Zepeda )

In addition we have a number of related projects that focus more on the cancer side, most of which are part of the Cancer Stem Cell Innovation Centre [link to cancerstemcell.no] , where Myklebost in Assistant Director.

We are also running the core facility for microarray and sequencing [link to http://core.rr-research.no/index.php?section=8] supported by grants from UiO, FUGE and Helse SørØst. 

The group is localised at the Institute for Cancer Research, where we have a more extensive presentation [link to kreftforskning.no/myklebost] .

Selected publications

 1.     Herz J, Hamann U, Rogne S, Myklebost O , Gausepohl H, Stanley KK ( 1988 ) Surface location and high affinity for    calcium of a 500 kDa liver membrane protein closely related to the LDL-recptor suggest a physiological role as lipoprotein receptor. EMBO J 7:4119-4127

  1. Berner J-M, Meza-Zepeda LA, Kools PFJ, Forus A, Schoenmakers EFPM, Van de Ven WJM, Fodstad Ø, Myklebost O . ( 1997 ) HMGIC, the gene for an architectural transcription factor, is amplified and rearranged in a subset of human sarcomas. Oncogene 14:2935-2941
  2. Meza-Zepeda LA, Berner JM , South A, Henriksen J, Dahlberg AB, Godager LH , Pedeutour F, Nizetic D, Forus A, Myklebost O ( 2001 ) Characterisation of ectopic sequences from tumour-associated, truncated HMGIC genes shows recurrent involvement of specific chromosomal regions. Genes Chromosomes Cancer 31: 264-73
  3. Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H, Zhao X, Vu BT, Qing W, Packman K, Myklebost O , Heimbrook DC, Vassilev LT ( 2006 ) Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer:  implications for therapy Proc Natl Acad Sci USA 103:1888-93
  4. The MAQC Consortium [including Myklebost O ] ( 2006 ) The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements Nature Biotech 24: pp1151 - 1161
  5. Meza-Zepeda LA , Noer A, Dahl JA, Micci F, Myklebost O , Collas P ( 2008 ) High-resolution analysis of genetic stability of human adipose tissue stem cells cultured to senescence. J Cell Mol Med 12:553-63
  6. Lehne G, Grasmo-Wendler UH , Berner JM , Meza-Zepeda LA , Adamsen BL, Flack A, Reiner A, Clausen OPF, Hovig E, Myklebost O ( 2009 ) Upregulation of stem cell genes in multidrug resistant K562 leukemia cells Leukemia Res 33:1379-85
  7. Tenstad E , Tourovskaia A, Folch A, Myklebost O , Rian E ( 2010 ) Extensive adipogenic and osteogenic differentiation of patterned human mesenchymal stem cells in a microfluidic device. Lab on a Chip 10, 1401-1409
  8. Eide MB, Liestøl K, Lingjærde OC, Hystad M, Kresse SH, Meza-Zepeda L, Myklebost O , Aamot HV, Holte H, Smeland EB, Delabie J ( 2010 ) DNA copy number alterations reveal potential for higher grade transformation in Follicular lymphoma and confirm parallel evolution of tumor cell clones. Blood  116:1489-97
  9. Henriksen J, Stabell M, Meza-Zepeda LA, Lauvrak SAU , Kassem M, Myklebost O ( 2010 ) Identification of target genes for wild type and truncated HMGA2 in mesenchymal stem-like cells BMC Cancer , 10:329

More  
 
>> Print this page